PND13 A COST-EFFECTIVENESS ANALYSIS OF NATALIZUMAB VS. INTERFERON-BETA AND GLATIRAMER ACETATE IN PATIENTS WITH ACTIVE RELAPSING-REMITTING MULTIPLE SCLEROSIS CURRENTLY FAILING ON EXISTING THERAPY
May 1, 2008, 00:00
10.1016/S1098-3015(10)70446-0
https://www.valueinhealthjournal.com/article/S1098-3015(10)70446-0/fulltext
Title :
PND13 A COST-EFFECTIVENESS ANALYSIS OF NATALIZUMAB VS. INTERFERON-BETA AND GLATIRAMER ACETATE IN PATIENTS WITH ACTIVE RELAPSING-REMITTING MULTIPLE SCLEROSIS CURRENTLY FAILING ON EXISTING THERAPY
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)70446-0&doi=10.1016/S1098-3015(10)70446-0
First page :
Section Title :
Open access? :
No
Section Order :
162